ticlopidine has been researched along with Heart Valve Diseases in 12 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Heart Valve Diseases: Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).
| Excerpt | Relevance | Reference |
|---|---|---|
| "There were two episodes of thromboembolism in the ticlopidine group at 1 month and 6 months respectively, with a linearized incidence of 0." | 9.08 | Prevention of thromboembolism with ticlopidine shortly after valve repair or replacement with a bioprosthesis. ( Agredo, J; Aramendi, JL; Larrarte, C; Llorente, A; Pijoan, J, 1998) |
| "There were two episodes of thromboembolism in the ticlopidine group at 1 month and 6 months respectively, with a linearized incidence of 0." | 5.08 | Prevention of thromboembolism with ticlopidine shortly after valve repair or replacement with a bioprosthesis. ( Agredo, J; Aramendi, JL; Larrarte, C; Llorente, A; Pijoan, J, 1998) |
| " The patient evolved with neutropenia induced by ticlopidine after 10 days of treatment." | 3.71 | Fibroelastoma of the mitral valve as a cause of transient ischemic stroke. ( Alessi, A; Bertolin Précoma, D; Fontoura, D; Gomes de Carvalho, R; Oliveira, LR; Zanis Neto, J; Zapparoli, M, 2001) |
| "Removal of the thrombus and maze procedure were performed at the same time." | 2.40 | [A case of mobile left atrial thrombus without mitral valve disease]. ( Asada, K; Hasegawa, Y; Kodama, T; Kondou, K; Matsuyama, N; Minohara, S; Okamoto, J; Okamoto, K; Sasaki, S; Sawada, Y, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 3 (25.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Windecker, S | 1 |
| Tijssen, J | 1 |
| Giustino, G | 1 |
| Guimarães, AH | 1 |
| Mehran, R | 1 |
| Valgimigli, M | 1 |
| Vranckx, P | 1 |
| Welsh, RC | 1 |
| Baber, U | 1 |
| van Es, GA | 1 |
| Wildgoose, P | 1 |
| Volkl, AA | 1 |
| Zazula, A | 1 |
| Thomitzek, K | 1 |
| Hemmrich, M | 1 |
| Dangas, GD | 1 |
| Payanam Ramachandra, U | 1 |
| Shenoy, SJ | 1 |
| Arumugham, S | 1 |
| Sparling, JM | 1 |
| Resnic, FS | 1 |
| Gendlin, GE | 1 |
| Tronina, OA | 1 |
| Storozhakov, GI | 1 |
| Jessup, DB | 1 |
| Coletti, AT | 1 |
| Muhlestein, JB | 1 |
| Barry, WH | 1 |
| Shean, FC | 1 |
| Whisenant, BK | 1 |
| García-Rinaldi, R | 1 |
| Toyohira, H | 1 |
| Nakamura, K | 1 |
| Kariyazono, H | 1 |
| Yamada, K | 1 |
| Moriyama, Y | 1 |
| Shimokawa, S | 1 |
| Saigenji, H | 1 |
| Taira, A | 1 |
| Matsuyama, N | 1 |
| Asada, K | 1 |
| Kondou, K | 1 |
| Kodama, T | 1 |
| Minohara, S | 1 |
| Hasegawa, Y | 1 |
| Sawada, Y | 1 |
| Okamoto, J | 1 |
| Okamoto, K | 1 |
| Sasaki, S | 1 |
| Aramendi, JL | 1 |
| Agredo, J | 1 |
| Llorente, A | 1 |
| Larrarte, C | 1 |
| Pijoan, J | 1 |
| Alessi, A | 1 |
| Gomes de Carvalho, R | 1 |
| Bertolin Précoma, D | 1 |
| Fontoura, D | 1 |
| Oliveira, LR | 1 |
| Zanis Neto, J | 1 |
| Zapparoli, M | 1 |
| Takayama, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes[NCT02556203] | Phase 3 | 1,653 participants (Actual) | Interventional | 2015-12-16 | Terminated (stopped due to Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 83 |
| Antiplatelet | 68 |
Composite of BARC 2,3 or 5 bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 148 |
| Antiplatelet | 85 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 14 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 68 |
| Antiplatelet | 63 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 105 |
| Antiplatelet | 78 |
ISTH major bleeds (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 49 |
| Antiplatelet | 30 |
The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety). (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 137 |
| Antiplatelet | 100 |
PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding. (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 46 |
| Antiplatelet | 31 |
Composite of TIMI major and minor bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 42 |
| Antiplatelet | 24 |
2 reviews available for ticlopidine and Heart Valve Diseases
| Article | Year |
|---|---|
[Antithrombotic therapy in patients with prosthetic heart valves].
Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Drug Monitoring; Heart Valve Diseases | 2010 |
[A case of mobile left atrial thrombus without mitral valve disease].
Topics: Aged; Atrial Fibrillation; Cardiac Surgical Procedures; Female; Fibrinolytic Agents; Heart Atria; He | 1997 |
3 trials available for ticlopidine and Heart Valve Diseases
| Article | Year |
|---|---|
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
[Significance of combined use of anticoagulants and antiplatelet agents in the early stage after prosthetic valve replacement].
Topics: Adult; Aged; Anticoagulants; Aspirin; Blood Coagulation; Depression, Chemical; Drug Therapy, Combina | 1995 |
Prevention of thromboembolism with ticlopidine shortly after valve repair or replacement with a bioprosthesis.
Topics: Aortic Valve; Bioprosthesis; Female; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Huma | 1998 |
7 other studies available for ticlopidine and Heart Valve Diseases
| Article | Year |
|---|---|
Improved Pig Model to Evaluate Heart Valve Thrombosis.
Topics: Animals; Aspirin; Blood Coagulation; Blood Platelets; Clopidogrel; Disease Models, Animal; Heart Val | 2016 |
Testing a no-warfarin heart valve.
Topics: Anticoagulants; Aspirin; Clopidogrel; Heart Valve Diseases; Heart Valve Prosthesis; Humans; Platelet | 2006 |
Highlights from Transcatheter Cardiovascular Therapeutics 2009: San Francisco, California, September 21 to 25, 2009.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiac Surgical Procedures; Clinical Trial | 2010 |
Elective coronary angiography and percutaneous coronary intervention during uninterrupted warfarin therapy.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Atrial Fibrillation; Cardia | 2003 |
Clopidogrel-aspirin inhibit the thrombogenicity of St. Jude mechanical aortic prostheses.
Topics: Aspirin; Clopidogrel; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Humans; Patient Sel | 2006 |
Fibroelastoma of the mitral valve as a cause of transient ischemic stroke.
Topics: Adult; Female; Fibroma; Heart Neoplasms; Heart Valve Diseases; Humans; Ischemic Attack, Transient; M | 2001 |
[Antithrombogenic therapy based on the study of the changes in platelet aggregability and blood coagulability in the early period after prosthetic valve replacement].
Topics: Adult; Anticoagulants; Blood Coagulation; Dipyridamole; Female; Heart Valve Diseases; Heart Valve Pr | 1985 |